Neuraceq
Authorised
This medicine is authorised for use in the European Union
florbetaben (18F)
MedicineHumanAuthorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
This is a summary of the European public assessment report (EPAR) for Neuraceq. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Neuraceq.
For practical information about using Neuraceq, patients should read the package leaflet or contact their doctor or pharmacist.
Neuraceq is a solution for injection that contains the active substance florbetaben (18F); it is for diagnostic use only.
Neuraceq is used during brain scans in patients with memory problems so that doctors can see whether or not they have significant amounts of ??amyloid plaques in the brain. ?-amyloid plaques are deposits sometimes present in the brain of people with memory problems caused by dementia (such as Alzheimer’s disease, Lewy-body dementia and Parkinson’s disease dementia) and also in the brain of some elderly people with no symptoms. The type of scan used with Neuraceq is called positron-emission tomography (PET).
Neuraceq can only be obtained with a prescription, and PET scans with Neuraceq should only be requested by doctors experienced in the management of patients with diseases such as Alzheimer’s and other dementias. The medicine is given by injection into a vein about 90 minutes before obtaining an image from a PET scan. After the image is obtained, it is read by physicians specially trained in interpreting PET scans with Neuraceq. Patients should discuss the results of their PET scan with their doctor.
The active substance in Neuraceq, florbetaben (18F), is a type of medicine known as a radiopharmaceutical that emits low amounts of radiation and works by targeting and attaching to ??amyloid plaques in the brain. After it attaches to the plaques, the radiation it emits can be detected by the PET scanner, enabling doctors to see whether or not significant amounts of plaques are present.
If few or no ?-amyloid plaques are seen in the PET scan (a negative scan), the patient is unlikely to have Alzheimer’s disease. However, a positive scan on its own is not sufficient to make a diagnosis in patients with memory problems, as plaques may be seen with several types of dementia and also in some elderly people with no symptoms. Doctors will therefore need to use the scans together with clinical evaluation.
Neuraceq has been investigated in one main study involving 216 volunteers divided into two groups: a group of healthy young people and a group of patients nearing the end of their lives who had consented to autopsies when they died; 41 volunteers (10 healthy young people and 31 patients) completed the study and were included in the results. The study looked at sensitivity and specificity of the PET scans (how well they identified volunteers with plaques in the brain and how accurate they were in distinguishing them from those who did not).
PET scans with Neuraceq were shown to have high specificity and sensitivity when used for identifying patients with significant amounts of ?-amyloid plaques in the brain. At the planned end of the study, 31 patients had died and had autopsies carried out on them to prove whether or not they had significant amounts of ?-amyloid plaques in their brains. When the results of the autopsies were compared with the PET scans, the scans were shown to have a sensitivity of 77.4% and a specificity of 94.2%. This means that the PET scans were able to correctly identify as positive 77.4% of the cases where patients had significant amounts of plaques, and that almost all patients without significant plaques were correctly rated as negative. These data were further supported by the results from additional patients analysed after completion of the study.
The most common side effects with Neuraceq (which may affect up to 1 in 10 people) are pain, irritation and reddening of the skin at the site of injection. For the full list of all side effects and restrictions with Neuraceq, see the package leaflet. Neuraceq delivers a very low amount of radiation with minimal risk of cancer or any hereditary abnormalities.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Neuraceq’s benefits are greater than its risks and recommended that it be approved for use in the EU. Results from the main study demonstrated that PET scans with Neuraceq have high sensitivity and specificity for detecting ?-amyloid plaques in the brain, with results of the scans closely reflecting what was seen at autopsy. This is regarded as a significant improvement in the diagnosis of patients with memory problems who are being evaluated for Alzheimer’s disease and other types of dementia. There is however a risk of false positive results, and therefore Neuraceq should not be used as the sole diagnostic method for dementia, but in conjunction with clinical evaluation. With regard to the safety profile of Neuraceq, this was considered reassuring, with the most common adverse events being related to injection site reactions.
The CHMP did however note that, due to the limited effects of currently available treatments for Alzheimer’s disease, there is no strong evidence that early diagnosis following PET scans with Neuraceq and early management of treatment will improve patient outcomes. In addition, the usefulness of Neuraceq in predicting the development of Alzheimer’s disease in patients with memory problems or in monitoring patients’ response to treatment has not been established.
A risk management plan has been developed to ensure that Neuraceq is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Neuraceq, including the appropriate precautions to be followed by healthcare professionals and patients.
Further information can be found in the summary of the .
The European Commission granted a marketing authorisation valid throughout the European Union for Neuraceq on 20 February 2014.
For more information about treatment with Neuraceq, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Product information
Latest procedure affecting product information:
EMA/VR/0000225729
31/10/2024
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Neuraceq
- Active substance
- florbetaben (18F)
- International non-proprietary name (INN) or common name
- florbetaben (18F)
- Therapeutic area (MeSH)
- Radionuclide Imaging
- Alzheimer Disease
- Anatomical therapeutic chemical (ATC) code
- V09AX06
Pharmacotherapeutic group
Diagnostic radiopharmaceuticalsTherapeutic indication
This medicinal product is for diagnostic use only.
Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of ? amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation.
A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.
News on Neuraceq
Topics
This page was last updated on